Zusammenfassung
Obwohl der Einfluß des Hodens auf Wachstum und Funktion der Prostata bereits im 19. Jahrhundert vermutet worden war, konnte dies erst durch die Pionierarbeiten von Huggins u. Stevens bestätigt werden. Es entstand das Konzept der Androgenabhängigkeit des Prostatagewebes [14].
Unterstützt durch den Jubiläumsfonds der Österreichischen Nationalbank (No. 3776)
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Asselin J, Labrie F, Gourdeau J, Bonne C, Raynaud JP (1976) Binding of 3H- methyltrienolone (R-1881) in rat prostate and human benign prostatic hypertrophy ( BPH ). Steroids 28: 449–459
Barrack ER, Coffey DS (1980) The specific binding of estrogens and androgens to the nuclear matrix of sex hormone responsive tissues. J Biol Chem 255: 7265–7275
Bartsch G, Müller HR, Oberholzer M, Rohr HP (1979) Light microscopic stereological analysis of the normal human prostate and of benign prostate hyperplasia. J Urol 122: 487–491
Bonne C, Raynaud JP (1975) Methyltrienolone, a specific ligand for cellular androgen receptors. Steroids 26: 227–232
Bruchovsky N, Lesser B, Van Doom E, Craven S (1975) Hormonal effects on cell proliferation in rat prostate. Vitam Horm 33: 61–102
Bruchovsky N, Callaway T, Lieskovsky G, Rennie PS (1980) Markers of androgen action in human prostate: potential use in the clinical assessment of prostatic carcinoma. In: Witliff JL, Dapunt O (eds) Steroid receptors and hormone dependent neoplasia. Masson Publ USA, New York, pp 121–132
Caine M, Perlberg S, Gordon R (1975) The treatment of benign prostatic hypertrophy with flutamide (SCH-13521): A placebo controlled study. J Urol 114: 564–568
Corbin A (1982) From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents. Yale J Biol Med 55: 27–47
Cowan RA, Cowan SK, Grant JK, Elder H Y (1977) Biochemical investigations of separated epithelium and stroma from benign prostatic hyperplastic tissue. J Endocrinol 74: 111–116
De Krester DM, Catt KJ, Paulsen CA (1971) Studies on the in vitro testicular binding of iodinated luteinizing hormone in rats. Endocrinology 80: 332–337
Dhom G (1976) Pathology and classification of prostatic carcinoma. In: Marberger H, Haschek H, Schirmer HKA, Colston JAC, Witkin E (eds) Prostatic disease. Alan R Liss, New York, p 111
Dufau ML, Catt KJ (1973) Extraction of soluble gonadotropin receptors from rat testis. Nature 242: 246–248
Huggins C, Hodge CV (1941) Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293–297
Huggins C, Stevens RA (1940) The effect of castration on benign hypertrophy of the prostate in man. J Urol 43: 705–714
Huggins C, Stevens RA, Hodges CV (1941) Studies on prostatic cancer. II. The effects of ca¬stration on advanced carcinoma of the prostate gland. Arch Surg 43: 209–223
Isaacs JT (1982) Cellular factors in the development of resistance to hormonal therapy. In: Bruchovsky N, Goldie JH (eds) Drug and hormone resistance in neoplasia, vol I. CRC Press, Boca Raton, pp 139–156
Isaacs JT, Coffey DS (1979) Androgenic control of prostatic growth: regulation of steroid levels. UICC Monogr (Prostatic Cancer) 48: 112–122
Isaacs JT, Coffey DS (1981) Adaptation versus selection on the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 41: 5070–5075
Isaacs JT, Coffey DS (1981) Androgen metabolism in the prostate: new concepts related to normal and abnormal growth. In: Altwein JE, Bartsch G, Jacobi GH (eds) Antihormone, Bedeutung in der Urologie. Zuckschwerdt, München, pp 3–20
Isaacs JT, Heston WDW, Weissmann RM, Coffey DS (1978) Animal models of the hormone- sensitive and insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT. Cancer Res 38: 4353–4359
Isaacs JT, Schulze H, Coffey DS (1987) Development of androgen resistance in prostatic cancer. In: Murphey GP, Khoury S, Kiiss R, Chatelain C, Denis L (eds) Prostate cancer, part A: Research, endocrine treatment, and histopathology. Liss, New York, pp 21–31
Jacobi GH, Altwein JE (1980) Androgenstoffwechsel im Prostatakarzinom: 3-Hydroxyste- roid-Dehydrogenase-Aktivität in Abhängigkeit vom Tumor-Differenzierungsgrad. Urol Intern 35: 194–205
Jacobo E, Schmidt JD, Weinstein SH, Flocks RH (1976) Comparison of flutamide (SCH-13521) and diethylstilbestrol in untreated advanced prostatic cancer. Urology 8: 231–233
Krieg M, Klötzl G, Kaufmann J, Voigt KD (1981) Stroma of human benign prostatic hyperplasia: preferential tissue for androgen metabolism and oestrogen binding. Acta Endocrinol 96: 422–432
Ling V (1982) Genetic basis of drug resistance in mammalian cells. In: Bruchovsky N, Goldie JH (eds) Drug and hormone resistance in neoplasia, vol I. CRC Press, Boca Raton, pp 1–19
MacDonald PC, Madden JD, Brenner PF, Wilson JD, Siiteri PK (1979) Origin of estrogen in normal men and in women with testicular féminisation. J Clin Endocrinol Metab 49: 905–916
Mackler MA, Liberti JP, Smith MJV, Koontz WW, Prout GR (1972) The effect of orchiectomy and various doses of stilbestrol on plasma testosterone levels in parents with carcinoma of the prostate. Invest Urol 9: 423 – 425
Means AR, Vaitukaitis JL (1972) Peptide hormone receptors: specific binding of 3H-FSH to testis. Endocrinology 90: 39–46
Menon M, Tananis CE, Hicks LL, Hawkins EF, McLoughlin HG, Walsh PC (1978) Characterisation of the binding of a potent synthetic androgen methyltrienolone, to human tissues. J Clin Invest 61: 150–162
Morfin RF, Leav I, Chavles JF, Cavazos LF, Ofner P, Floch HH (1977) Correlative study of the morphology and C19-steroid metabolism of benign and cancerous human prostatic tissue. Cancer 39: 1517–1534
Nesbit RM, Baum WC (1950) Endocrine control of prostatic carcinoma; clinical and statistical survey of 1818 cases. JAMA 143: 1317–1320
Prout GR, Irwin RJ, Kliman B, Daly JJ, MacLaughlin RA, Griffin PP (1975) Prostatic cancer and SCH-13521. II. Histological alterations and the pituitary gonadal axis. J Urol 113: 834–840
Prout GR, Kliman B, Daly JJ, MacLaughlin RA, Griffin PD (1976) In vitro uptake of 3H- testosterone and its conversion to dihydrotestosterone by prostatic carcinoma and other tissues. J Urol 116: 603–610
Rennie PS (1982) Biochemical aspects of androgen resistance. In: Bruchovsky N, Goldie JH (eds) Drug and hormone resistance in neoplasia, vol I. CRC Press, Boca Raton, pp 95–121
Robinson MRG, Thomas BS (1971) Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma. Br Med J 4: 391–394
Rohr HP, Bartsch G (1980) Human benign prostatic hyperplasia: a stromal disease. Urology 16: 625–633
Romijn JC, Oishi K, Belt de Vries J, Schweikert U, Mulder E, Schröder FH (1980) Androgen metabolism and androgen receptors in separated epithelium and stroma of the human prostate. In: Schröder FH, de Voogt HJ (eds) Steroid receptors, metabolism and prostatic cancer. Excerpta Medica, Amsterdam, pp 134–139
Rosen V, Jung I, Baulieu EE, Roberl P (1975) Androgen binding proteins in human benign prostate hypertrophy. J Clin Endocrinol Metab 41: 761–770
Schally AV, Arimura A, Kastin AJ (1973) The LH and FSH releasing hormone. In: Scow RO (ed) Endocrinology. Excerpta Medica, Amsterdam
Scheiber K, Mikuz G, Bartsch G (1984) Exocrine and endocrine functions in unilateral testicular disease. World J Urol 2: 251–254
Schulze H, Isaacs JT, Coffey DS (1986) A critical review of the concept of total androgen abla¬tion in the treatment of prostate cancer. In: Murphy G (ed) 2nd International Symposium on Prostatic Cancer. Alan R Liss, New York
Scott WW, Menon M, Walsh PC (1980) Hormonal therapy of prostatic cancer. Cancer 45: 1929–1936
Shain SA, Boesel RW (1978) Human prostate steroid hormone receptor quantitation: current methodology and possible utilization as a clinical discriminant in carcinoma. Invest Urol 16: 169–174
Shain SA, Boesel RW (1978) Androgen receptor content of the normal and hyperplastic canine prostate. J Clin Invest 61: 645–660
Shain SA, Boesel RW, Lamm DL, Rodwin HM (1978) Characterization of unoccupied (R) and occupied ( RA) androgen binding components of the hyperplastic human prostate. Steroids 31: 541–556
Shearer RJ, Hendry WF, Sommer IF, Ferguson JD (1973) Plasma testosterone: An accurate monitor of hormone treatment in prostatic cancer. Br J Urol 45: 668–677
Siiteri PK, Wilson JD (1970) Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest 49: 1737–1745
Sirett DAN, Grant JK (1978) Androgen binding in cytosols and nuclei of human benign hyperplastic tissue. J Endocrinol 77: 101–110
Skipper HE, Schabel FM, Lloyd MM (1978) Selection and overgrowth of specifically and permanently drug-resistant tumor cells. Exp Ther Kinetics 15: 207–217
Smolev JK, Heston WDW, Scott WW, Coffey DS (1977) Characterization of the Dunning R-3327-H prostatic adenocarcinoma: An appropriate animal model for prostatic cancer. Cancer Treat Rep 61: 273–287
Trachtenberg J, Bujnovszky P, Walsh PC (1982) Androgen receptor content of normal and hyperplastic human prostate. J Clin Endocrinol Metab 54: 17–21
Veterans Administration Co-operative Urological Research Group (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011–1017
Wagner RK (1972) Characterisation and assay of steroid hormone receptors and steroid binding serum proteins by agar gel electrophoresis at low temperature. Hoppe Seylers Z Physiol Chem 253: 1235–1245
Walsh PC (1975) Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 2: 125–140
Walsh PC, Hicks LL (1979) Characterisation and measurement of androgen receptors in human prostatic tissue. Prog Clin Biol Res 33: 51–63
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Bartsch, G., Oefner, P.J., Eberle, J. (1990). Endokrine Therapie des fortgeschrittenen Prostatakarzinoms. In: Staehler, G., Fabricius, P.G. (eds) Das Prostatakarzinom. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-75654-2_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-75654-2_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-75655-9
Online ISBN: 978-3-642-75654-2
eBook Packages: Springer Book Archive